<DOC>
	<DOCNO>NCT02196467</DOCNO>
	<brief_summary>This Phase I/II clinical trial investigate whether transplantation normal myoblasts throughout one muscle ( extensor carpus radialis ) patient safe improve strength muscle . During Phase I/II , patient transplant myoblasts grown muscle biopsy donor keep frozen liquid nitrogen . Thirty million myoblasts inject per cm cube progressively high surface radialis ( i.e. , 3 , 6 9 cm2 ) . The contralateral muscle inject saline serve control . The strength muscle measure 3 month post transplantation verify whether myoblast transplantation improve strength muscle . If significant strength improvement , protocol terminate immediately patient . If significant strength improvement , patient maintain immunosuppression 6 month post transplant strength re-evaluated .</brief_summary>
	<brief_title>Transplantation Myoblasts Duchenne Muscular Dystrophy ( DMD ) Patients</brief_title>
	<detailed_description>Duchenne Muscular Dystrophy ( DMD ) degenerative disease genetic origin , due mutation gene cod protein dystrophin . This mutation lead deficiency dystrophin myofibers , cause progressive muscle degeneration follow mechanism : ( 1 ) dystrophin deficiency lead myofibers vulnerable muscle contraction-relaxation , cause frequent damage necrosis myofibers ; ( 2 ) necrosis follow myofiber regeneration , long regenerative capacity muscle exhaust ; ( 3 ) regenerative capacity muscle exhaust , myofibers become atrophic ultimately lose ; ( 4 ) fibrosis fat infiltration replace lose myofibers . This progressive muscle destruction take place muscle limbs trunk , lead progressive loss muscle strength , musculotendinous contracture , restrictive respiratory insufficiency premature death 17 30 year . The transplantation myoblasts obtain healthy donor potential treatment DMD . Following intramuscular injection , donor myoblasts fuse myofibers patient , introduce normal dystrophin gene . In previous Phase 1A clinical trial , investigator prove transplantation myoblasts grow muscle biopsy healthy donor introduce normal dystrophin gene DMD myofibers , consequent expression normal dystrophin mRNA restoration dystrophin protein several myofibers . The aim Phase I/II clinical trial investigate whether transplantation normal myoblasts throughout one muscle ( case , extensor carpus radialis ) DMD patient safe improve strength muscle . The patient transplant myoblasts grown muscle biopsy healthy donor . Thirty million myoblasts inject per cm cube progressively higher volume muscle ( i.e. , 3 , 6 9 cm cube ) . The contralateral muscle inject saline control . The patient investigator blind side injected cell . The strength muscle measure 3 month post transplant verify myoblast transplantation increase muscle strength . If significant strength increase , protocol terminate immediately patient . If significant strength increase , patient maintain immunosuppression 6 month muscle strength re-evaluated . The objective Phase I/II clinical trial DMD patient thus : Primary objective : To evaluate safety procedure high-density injection donor myoblasts throughout muscle ( immunosuppression tacrolimus ) . Secondary objective : 1 . To evaluate whether myoblast transplantation result presence dystrophin-positive myofibers donor origin . 2 . To evaluate whether myoblast transplantation improve muscle strength prevent slow progression muscle weakness show follow parameter : 2.1 ) Increase voluntary strength subject 's wrist extension do extensor carpus radialis 12 24 week myoblast transplantation compare pre-transplant value muscle . 2.2 ) Reduction fatigue voluntary strength subject 's wrist extension do extensor carpus radialis 12 24 week myoblast transplantation compare pre-transplant fatigue value muscle . 2.3 ) Reduce progression muscle weakness myoblast inject muscle compare control contralateral muscle . 3 . To verify long term effectiveness tacrolimus immunosuppression control acute rejection myoblast transplantation ( examine presence muscle fiber express normal dystrophin absence specific immune response )</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>A clinical diagnosis DMD must confirm ( i.e. , support confirmation demonstrate identification mutation dystrophin gene compatible DMD presence le 10 % dystrophin positive fiber muscle biopsy subject DMD ) . The subject old 16 year age . Male If corticosteroid , stable dose must maintain 6 month prior myoblast transplantation throughout trial A potential haplotype compatible donor ( father , mother , brother sister 18 year old ) available . The subject must able move wrist , MRC scale score great equal 2 . Subject must vaccinate pneumococcus Haemophilus influenzae . For subject sexually active , willingness abstain sexual intercourse employ barrier medical method contraception duration study . For subject need assist ventilation , stable regimen noninvasive ventilation parameter 3 month prior first myoblast transplantation anticipation stable regimen throughout study . Written inform consent subject donor . An abnormal sensory examination Persisting abnormal value hemogram ( red blood cell , white blood cell , hemoglobin platelet laboratory normal range ) . A history chronic infection . Abnormal glycosylated hemoglobin level and/or fast blood glucose ( values laboratory normal range ) Previous neoplasia . Previous tuberculosis potential carrier latent tuberculosis . Any clinically significant cardiac , endocrine , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease determine Investigator related DMD Previous history renal problem laboratory analysis suggestive renal problem ( cystatin C , blood urea nitrogen , electrolytes laboratory normal range ) . Previous biopsy intramuscular injection extensor carpus radialis . Subject participate phase 1A myoblast transplantation The subject use drug compatible tacrolimus ( see section 6 `` Concomitant medication '' protocol ) within last month . If subject previously use one drug , washout period onset tacrolimus least 1 month . Subject test positive HIV1 , HIV2 , antigen HIV1 , HBC ( hepatitis B surface antigen ( HBsAg ) hepatitis B core antigen ) HCV , HTLV1 antiHTLV2 . The subject submit electromyography extensor carpus radialis , within last 6 month . There preexist antibody subject serum donor lymphocyte . Any change ( initiation , dose adjustment , interruption discontinuation ) medication may affect muscle function ( eg . Losartan , coenzyme Q10 , green tea extract , idebenone , creatine , nutritional supplement , etc . ) within 3 month first myoblast transplantation . Any change cardiac medication ( ACE inhibitor , betablocker , etc . ) within 3 month first myoblast transplantation . Any surgery fracture upper extremity within 3 month prior first myoblast transplantation plan surgery course trial . No haplotype compatible donor available . Unwillingness inability subject understand comply requirement protocol opinion Investigator sponsor . Previous tuberculosis potential carrier latent tuberculosis . Previous treatment investigational product within 6 month myoblast transplantation .</criteria>
	<gender>Male</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>myoblast</keyword>
	<keyword>transplantation</keyword>
	<keyword>strength</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>immunosuppression</keyword>
</DOC>